News | August 12, 2021
KK Pant is the new NPPA chairman
It plays a pivotal role in monitoring pharmaceutical pricing
It plays a pivotal role in monitoring pharmaceutical pricing
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
